Literature DB >> 33499840

Short chain fatty acids and colon motility in a mouse model of irritable bowel syndrome.

Ilnar F Shaidullov1, Dina M Sorokina1, Farit G Sitdikov1, Anton Hermann2, Sayar R Abdulkhakov1, Guzel F Sitdikova3.   

Abstract

BACKGROUND: Irritable bowel syndrome (IBS) is defined as a multifactorial disorder associated with visceral hypersensitivity, altered gut motility and dysfunction of the brain-gut axis. Gut microbiota and its metabolites are proposed as possible etiological factors of IBS. Short chain fatty acids (SCFAs) induce both inhibitory and stimulatory action on colon motility, however, their effects on the IBS model were not investigated. The aim of our study was to investigate the level of SFCAs in feces and their effects on colon motility in a mouse model of IBS.
METHODS: IBS model was induced in mice by intracolonic infusion of 1% acetic acid during the early postnatal period. Mice colon hypersensitivity was assessed by the threshold of the abdominal withdrawal reflex in response to colorectal distention. Colon contractility was studied using proximal colon specimens in isometric conditions. Transit rates were assessed by the pellet propulsion in the isolated colon. Concentrations of SCFAs in feces were measured using gas-liquid chromatography.
RESULTS: The concentration of SCFAs in feces of IBS model mice was higher compared to the control group. Visceral sensitivity to colorectal distension and colonic transit rate were increased indicating IBS with predominant diarrhea. The frequency and amplitude of spontaneous contractions of proximal colon segments from IBS mice were higher, but carbachol induced contractions were lower compared to control. During acute application of SCFAs (sodium propionate, sodium acetate or butyric acid) dose-dependently (0.5-30 mM) decreased tonic tension, frequency and amplitude of spontaneous and carbachol-evoked contractions. In the mouse IBS group the inhibitory effects SCFAs on spontaneous and carbachol-evoked contractions were less pronounced. At the same time intraluminal administration of butyrate (5 mM) increased the transit rate in the colon of both groups, but its stimulatory effect was more pronounced in mouse IBS model group.
CONCLUSION: Our data indicate that the increased transit rate in the mouse IBS model group is associated with a disbalance of activating and inhibiting action of SCFAs due to chronically elevated SCFA levels, which may impact the pathogenesis of IBS with predominant diarrhea syndrome.

Entities:  

Keywords:  Butyric  acid; Colonic transit; Irritable bowel syndrome (IBS); Mouse colon motility; Short chain fatty acids (SCFAs); Sodium propionate; Sodium  acetate

Mesh:

Substances:

Year:  2021        PMID: 33499840      PMCID: PMC7836204          DOI: 10.1186/s12876-021-01613-y

Source DB:  PubMed          Journal:  BMC Gastroenterol        ISSN: 1471-230X            Impact factor:   3.067


  67 in total

Review 1.  Matching models to data: a receptor pharmacologist's guide.

Authors:  David A Hall; Christopher J Langmead
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 2.  Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides.

Authors:  D L Topping; P M Clifton
Journal:  Physiol Rev       Date:  2001-07       Impact factor: 37.312

3.  Butyrate enemas enhance both cholinergic and nitrergic phenotype of myenteric neurons and neuromuscular transmission in newborn rat colon.

Authors:  Etienne Suply; Philine de Vries; Rodolphe Soret; François Cossais; Michel Neunlist
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-04-05       Impact factor: 4.052

4.  Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome.

Authors:  C Tana; Y Umesaki; A Imaoka; T Handa; M Kanazawa; S Fukudo
Journal:  Neurogastroenterol Motil       Date:  2009-11-10       Impact factor: 3.598

5.  Antinociceptive and antidiarrheal effects of pioglitazone in a rat model of diarrhoea-predominant irritable bowel syndrome: role of nitric oxide.

Authors:  Pedram Paragomi; Reza Rahimian; Mohammad Hossein Kazemi; Mohammad Hadi Gharedaghi; Amin Khalifeh-Soltani; Saeedeh Azary; Abbas Norouzi Javidan; Kamran Moradi; Stephen Sakuma; Ahmad Reza Dehpour
Journal:  Clin Exp Pharmacol Physiol       Date:  2014-02       Impact factor: 2.557

Review 6.  What Is New in Rome IV.

Authors:  Max J Schmulson; Douglas A Drossman
Journal:  J Neurogastroenterol Motil       Date:  2017-04-30       Impact factor: 4.924

7.  Alterations in fecal short-chain fatty acids in patients with irritable bowel syndrome: A systematic review and meta-analysis.

Authors:  Qinghua Sun; Qiong Jia; Lijin Song; Liping Duan
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

8.  Adiposity, gut microbiota and faecal short chain fatty acids are linked in adult humans.

Authors:  J Fernandes; W Su; S Rahat-Rozenbloom; T M S Wolever; E M Comelli
Journal:  Nutr Diabetes       Date:  2014-06-30       Impact factor: 5.097

9.  The propionic acid and butyric acid in serum but not in feces are increased in patients with diarrhea-predominant irritable bowel syndrome.

Authors:  Zhenyi Tian; Xiaojun Zhuang; Mei Luo; Wei Yin; Lishou Xiong
Journal:  BMC Gastroenterol       Date:  2020-03-16       Impact factor: 3.067

10.  Inflammatory Bowel Disease-Associated Changes in the Gut: Focus on Kazan Patients.

Authors:  Giuseppe Lo Sasso; Lusine Khachatryan; Athanasios Kondylis; James N D Battey; Nicolas Sierro; Natalia A Danilova; Tatiana V Grigoryeva; Maria I Markelova; Dilyara R Khusnutdinova; Alexander V Laikov; Ilnur I Salafutdinov; Yulia D Romanova; Mariia N Siniagina; Ilya Yu Vasiliev; Eugenia A Boulygina; Valeriya V Solovyeva; Ekaterina E Garanina; Kristina V Kitaeva; Konstantin Y Ivanov; Darja S Chulpanova; Konstantin S Kletenkov; Alina R Valeeva; Alfiya Kh Odintsova; Maria D Ardatskaya; Rustam A Abdulkhakov; Nikolai V Ivanov; Manuel C Peitsch; Julia Hoeng; Sayar R Abdulkhakov
Journal:  Inflamm Bowel Dis       Date:  2021-02-16       Impact factor: 5.325

View more
  6 in total

Review 1.  Eosinophils, Hypoxia-Inducible Factors, and Barrier Dysfunction in Functional Dyspepsia.

Authors:  Suraj Hari; Grace L Burns; Emily C Hoedt; Simon Keely; Nicholas J Talley
Journal:  Front Allergy       Date:  2022-05-31

Review 2.  Gut microbiota-motility interregulation: insights from in vivo, ex vivo and in silico studies.

Authors:  Barbora Waclawiková; Agnese Codutti; Karen Alim; Sahar El Aidy
Journal:  Gut Microbes       Date:  2022 Jan-Dec

Review 3.  Polysaccharide Regulation of Intestinal Flora: A Viable Approach to Maintaining Normal Cognitive Performance and Treating Depression.

Authors:  Xinzhou Wang; Lu Cheng; Yanan Liu; Ruilin Zhang; Zufang Wu; Peifang Weng; Peng Zhang; Xin Zhang
Journal:  Front Microbiol       Date:  2022-03-11       Impact factor: 5.640

Review 4.  Role of gut microbiota-derived signals in the regulation of gastrointestinal motility.

Authors:  Zhipeng Zheng; Jingyi Tang; Yingnan Hu; Wei Zhang
Journal:  Front Med (Lausanne)       Date:  2022-07-22

5.  The Effect of Serine Protease Inhibitors on Visceral Pain in Different Rodent Models With an Intestinal Insult.

Authors:  Hannah Ceuleers; Nikita Hanning; Michelle De Bruyn; Joris G De Man; Heiko U De Schepper; Qian Li; Liansheng Liu; Steven Abrams; Annemieke Smet; Jurgen Joossens; Koen Augustyns; Ingrid De Meester; Pankaj J Pasricha; Benedicte Y De Winter
Journal:  Front Pharmacol       Date:  2022-06-02       Impact factor: 5.988

6.  No synergistic effect of fecal microbiota transplantation and shugan decoction in water avoidance stress-induced IBS-D rat model.

Authors:  Yangyang Meng; Ya Feng; Lu Hang; Yan Zhou; Enkang Wang; Jianye Yuan
Journal:  Front Microbiol       Date:  2022-09-12       Impact factor: 6.064

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.